On June 13, MSD announced that its PD-1 inhibitor, pabolizumab, has been approved by the China National Drug Administration and is combined with lumvatinib for arterial chemotherapy embolization to treat patients with unresectable non-metastatic hepatocellular carcinoma. The approval of this new indication is based on data from the phase III clinical trial LEAP-012 study.

Zhitongcaijing · 06/13/2025 02:41
On June 13, MSD announced that its PD-1 inhibitor, pabolizumab, has been approved by the China National Drug Administration and is combined with lumvatinib for arterial chemotherapy embolization to treat patients with unresectable non-metastatic hepatocellular carcinoma. The approval of this new indication is based on data from the phase III clinical trial LEAP-012 study.